RNA-directed targeting of AID in immunity and genomic integrity

RNA 引导的 AID 免疫和基因组完整性靶向

基本信息

  • 批准号:
    9095773
  • 负责人:
  • 金额:
    $ 42.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-02-01 至 2021-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): DNA double strand breaks (DSBs) constitute one of the most toxic lesions to occur in a cell. Unrepaired DSBs can either lead to cell death or can participate in chromosomal translocations that are hallmarks of many kinds of tumors, including lymphomas. Despite the toxicity associated with DSBs, during the immunoglobulin (Ig) gene diversification process of class switch recombination (CSR), DSBs are deliberately introduced into defined regions, called switch (S) regions, of the B cell genome, and a failure to introduce such DSBs leads to immunodeficiency syndromes. The DNA deaminase AID (activation induced cytidine deaminase) is essential for the generation of DSBs. While S regions (and the Ig gene associated variable region gene segments) are primary targets, AID has the potential to induce DSBs at non-Ig genes, including oncogenes. Such off-target DSBs are the major lesions behind the ontogeny of a large number of mature B cell lymphomas. Despite the relevance of AID targeting to both immunity and cancer, the molecular mechanisms underlying AID specificity are yet to be fully elucidated. We have now shown that noncoding RNA emanating from S regions act as molecular guides to recruit AID to S regions. This proposal tests the hypothesis that switch transcripts not only recruit AID to S regions to facilitate CSR but also sequester AID from other genomic regions to prevent collateral damage during B cell gene diversification. In aim 1, we test the notion that the RNA-guided recruitment of AID is critical fo CSR in vivo. In aim 2, we examine if RNA-guided AID recruitment serves to shelter the B cell genome from collateral AID-induced DNA damage. In aim 3, we design chimeric RNA molecules for ectopic targeting of AID. These studies will have far-reaching implications into our fundamental understanding of both immunity and how simple aberrations in the process could lead to B cell lymphomas.
 描述(由申请人提供):DNA双链断裂(DSB)是细胞中发生的毒性最大的损伤之一。未修复的DSB可以导致细胞死亡,也可以参与染色体易位,这是许多类型肿瘤的标志,包括淋巴瘤。尽管DSB具有毒性,但在类别转换重组(CSR)的免疫球蛋白(IG)基因多样化过程中,DSB被有意引入B细胞基因组的限定区域,称为转换(S)区域,并且未能引入此类DSB导致免疫缺陷综合征。DNA脱氨酶AID(活化诱导的胞苷脱氨酶)对于DSB的产生是必不可少的。虽然S区(和与IG基因相关的可变区基因片段)是主要靶点,但AID有可能在非IG基因(包括癌基因)处诱导DSB。这种脱靶DSB是大量成熟B细胞淋巴瘤个体发生背后的主要病变。尽管AID靶向免疫和癌症的相关性,但AID特异性的分子机制尚未完全阐明。我们现在已经证明,来自S区的非编码RNA作为分子向导将AID募集到S区。该提议检验了这样的假设,即转换转录物不仅将AID募集到S区域以促进CSR,而且还将AID与其他基因组区域隔离以防止B细胞基因多样化期间的附带损伤。在目标1中,我们测试了RNA引导的AID募集对体内CSR至关重要的概念。在目标2中,我们检查RNA引导的AID募集是否用于保护B细胞基因组免受附带的AIDS诱导的DNA损伤。在目标3中,我们设计嵌合RNA分子用于异位靶向AID。这些研究将对我们对免疫和免疫过程中简单的畸变如何导致B细胞淋巴瘤的基本理解产生深远的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jayanta Chaudhuri其他文献

Jayanta Chaudhuri的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jayanta Chaudhuri', 18)}}的其他基金

RNA-directed targeting of AID in immunity and cancer
RNA定向靶向AID在免疫和癌症中的作用
  • 批准号:
    10530805
  • 财政年份:
    2016
  • 资助金额:
    $ 42.85万
  • 项目类别:
RNA-directed targeting of AID in immunity and genomic integrity
RNA 引导的 AID 免疫和基因组完整性靶向
  • 批准号:
    9210606
  • 财政年份:
    2016
  • 资助金额:
    $ 42.85万
  • 项目类别:
RNA-directed targeting of AID in immunity and cancer
RNA定向靶向AID在免疫和癌症中的作用
  • 批准号:
    10664029
  • 财政年份:
    2016
  • 资助金额:
    $ 42.85万
  • 项目类别:
Mechanistic Elucidation of Class Switch Recombination and Somatic Hypermutation
类别转换重组和体细胞超突变的机制阐明
  • 批准号:
    10230368
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:
ELUCIDATION OF IMMUNOGLOBULIN CLASS SWITCH RECOMBINATION AND SOMATIC HYPERMUTATIO
免疫球蛋白类别转换重组和体细胞超突变的阐明
  • 批准号:
    7585561
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:
ELUCIDATION OF IMMUNOGLOBULIN CLASS SWITCH RECOMBINATION AND SOMATIC HYPERMUTATIO
免疫球蛋白类别转换重组和体细胞超突变的阐明
  • 批准号:
    8500117
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:
ELUCIDATION OF IMMUNOGLOBULIN CLASS SWITCH RECOMBINATION AND SOMATIC HYPERMUTATIO
免疫球蛋白类别转换重组和体细胞超突变的阐明
  • 批准号:
    7870360
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:
ELUCIDATION OF IMMUNOGLOBULIN CLASS SWITCH RECOMBINATION AND SOMATIC HYPERMUTATIO
免疫球蛋白类别转换重组和体细胞超突变的阐明
  • 批准号:
    8099602
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:
Mechanistic Elucidation of Class Switch Recombination and Somatic Hypermutation
类别转换重组和体细胞超突变的机制阐明
  • 批准号:
    10348783
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:
Elucidation of Immunoglobulin Class Switch Recombination
免疫球蛋白类别转换重组的阐明
  • 批准号:
    9172233
  • 财政年份:
    2009
  • 资助金额:
    $ 42.85万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 42.85万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了